| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00006123-200005000-00030 |
| P698 | PubMed publication ID | 10807250 |
| P50 | author | Ian F. Parney | Q47328401 |
| P2093 | author name string | Chang LJ | |
| Petruk KC | |||
| Farr-Jones MA | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1169-77; discussion 1177-8 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | Neurosurgery | Q7002693 |
| P1476 | title | Human glioma immunobiology in vitro: implications for immunogene therapy. | |
| P478 | volume | 46 |
| Q123031200 | Ed100 |
| Q123031202 | Ed104 |
| Q123031203 | Ed105 |
| Q123031204 | Ed106 |
| Q123031205 | Ed109 |
| Q123031206 | Ed110 |
| Q123031207 | Ed111 |
| Q123031208 | Ed113 |
| Q123031209 | Ed114 |
| Q123031211 | Ed116 |
| Q123031212 | Ed117 |
| Q123031213 | Ed118 |
| Q123031214 | Ed119 |
| Q123031215 | Ed120 |
| Q123031216 | Ed121 |
| Q54831956 | Ed147.BT |
| Q54831957 | Ed149.BT |
| Q123031219 | Ed77 |
| Q123031220 | Ed79 |
| Q123031221 | Ed84 |
| Q123031222 | Ed85 |
| Q123031223 | Ed93 |
| Q123031224 | Ed98 |
| Q123031225 | Ed99 |
| Q37093633 | A prospective comparative clinical study of peripheral blood counts and indices in patients with primary brain tumors |
| Q55473253 | Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. |
| Q34842204 | All in the head: obstacles for immune rejection of brain tumours |
| Q27024830 | An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma |
| Q30816567 | Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas |
| Q35113661 | Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma |
| Q34734197 | Changing boundaries in the treatment of malignant gliomas. |
| Q30784536 | Clinical immunotherapy for brain tumors |
| Q36325239 | Current immunotherapeutic strategies for central nervous system tumors |
| Q38418399 | Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma |
| Q43648101 | Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy |
| Q48440349 | Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas |
| Q31148056 | Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain |
| Q40464370 | Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. |
| Q34721575 | Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. |
| Q31079257 | GLI2 regulates TGF-β1 in human CD4+ T cells: implications in cancer and HIV pathogenesis |
| Q40863831 | Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF. |
| Q34361488 | Gene therapy of glioblastomas: from suicide to homicide |
| Q43598494 | Human Alloreactive CTL Interactions with Gliomas and with Those Having Upregulated HLA Expression from Exogenous IFN-γ or IFN-γ Gene Modification |
| Q46039988 | Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression o |
| Q55473284 | Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12. |
| Q37267793 | Immunotherapeutic approaches for glioma |
| Q91199920 | Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons |
| Q36273693 | Immunotherapy for malignant glioma: current approaches and future directions |
| Q34701587 | Immunotherapy of brain cancers: the past, the present, and future directions |
| Q40437156 | Impaired capacity for upregulation of MHC class II in tumor-associated microglia |
| Q35800497 | Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model |
| Q38925761 | Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model |
| Q35440540 | Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. |
| Q39389439 | Interleukin-6 is overexpressed and augments invasiveness of human glioma stem cells in vitro |
| Q37805181 | Is HCMV a tumor promoter? |
| Q33824394 | LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4 |
| Q37079854 | Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines |
| Q39670919 | Multi-walled Carbon Nanotube (MWCNT) Synthesis, Preparation, Labeling, and Functionalization |
| Q38161536 | Myeloid-derived suppressor cells in glioma |
| Q34770719 | Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. |
| Q34771514 | Non-cytotoxic therapies for malignant gliomas |
| Q34132823 | Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. |
| Q41434923 | RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells. |
| Q34309564 | Role of microglia in glioma biology |
| Q39924722 | The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model |
Search more.